TY - JOUR
T1 - Importance of the intestinal microbiota in ocular inflammatory diseases
T2 - A review
AU - Lin, Phoebe
N1 - Funding Information:
This study was supported by an unrestricted departmental funding from Research to Prevent Blindness (New York, NY). P.L. is also the recipient of an Alcon Research Institute Young Investigator Award and OHSU Physician-Scientist award, as well as recipient of a Thome Foundation award.
Funding Information:
National Institutes of Health, Grant/Award Number: P30 EY010572; Alcon Research Institute, Grant/Award Number: Young Investigator Award; Collins Medical Trust, Grant/Award Number: Award; Edward N. and Della L. Thome Memorial Foundation, Grant/Award Number: Program in Age-Related Macular Degeneration Researh; National Eye Institute, Grant/Award Numbers: K08 EY022948, P30 EY010572 ; Oregon Health & Science University, Grant/Award Number: Physician-Scientist Award; Research to Prevent Blindness, Grant/Award Numbers: Career Development Award, Unrestricted departmental funding
Publisher Copyright:
© 2019 Royal Australian and New Zealand College of Ophthalmologists
PY - 2019/4
Y1 - 2019/4
N2 - The purpose of this article is to review the literature on relationships between the intestinal microbiota and ocular inflammatory disease, specifically non-infectious uveitis and age-related macular degeneration. The importance of the intestinal microbiota in uveitis pathogenesis has been shown by multiple groups demonstrating that alterations in the microbiota induced by certain oral antibiotics results in reduced uveitis severity, and another group demonstrating that a commensal intestinal bacterial antigen activates retina-specific autoreactive T cells, potentially indicating a commensal trigger for uveitis. Additionally, commensal intestinal bacterial metabolite short chain fatty acids can be utilized to suppress autoimmune uveitis. Age-related macular degeneration is associated with intestinal dysbiosis, which is partially influenced by genetic risk alleles and AREDS supplementation. Strategies for therapeutically targeting the intestinal microbiota might involve several approaches, including the use of antibiotics, dietary changes, drugs that supplement beneficial bacterial metabolites or target causative bacterial strains, dietary strategies or faecal microbial transplantation. In summary, the intestinal microbiota are at the cross-roads of genetic and environmental factors that can promote ocular conditions such as non-infectious uveitis and age-related macular degeneration, partially via its dynamic influence on mucosal and systemic immunity. The intestinal microbiome thus represents a salient potential target for therapeutic modulation to treat these potentially blinding conditions.
AB - The purpose of this article is to review the literature on relationships between the intestinal microbiota and ocular inflammatory disease, specifically non-infectious uveitis and age-related macular degeneration. The importance of the intestinal microbiota in uveitis pathogenesis has been shown by multiple groups demonstrating that alterations in the microbiota induced by certain oral antibiotics results in reduced uveitis severity, and another group demonstrating that a commensal intestinal bacterial antigen activates retina-specific autoreactive T cells, potentially indicating a commensal trigger for uveitis. Additionally, commensal intestinal bacterial metabolite short chain fatty acids can be utilized to suppress autoimmune uveitis. Age-related macular degeneration is associated with intestinal dysbiosis, which is partially influenced by genetic risk alleles and AREDS supplementation. Strategies for therapeutically targeting the intestinal microbiota might involve several approaches, including the use of antibiotics, dietary changes, drugs that supplement beneficial bacterial metabolites or target causative bacterial strains, dietary strategies or faecal microbial transplantation. In summary, the intestinal microbiota are at the cross-roads of genetic and environmental factors that can promote ocular conditions such as non-infectious uveitis and age-related macular degeneration, partially via its dynamic influence on mucosal and systemic immunity. The intestinal microbiome thus represents a salient potential target for therapeutic modulation to treat these potentially blinding conditions.
KW - age-related macular degeneration
KW - microbiome
KW - uveitis
UR - http://www.scopus.com/inward/record.url?scp=85063404073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063404073&partnerID=8YFLogxK
U2 - 10.1111/ceo.13493
DO - 10.1111/ceo.13493
M3 - Review article
C2 - 30834680
AN - SCOPUS:85063404073
SN - 1442-6404
VL - 47
SP - 418
EP - 422
JO - Australian and New Zealand Journal of Ophthalmology
JF - Australian and New Zealand Journal of Ophthalmology
IS - 3
ER -